Key points from article :
Clinical trial focused on mesenchymal stem cells (MSCs) attraction to damage and inflammation.
Approach uses their signaling and ability to recruit microglia in order to reduce amyloid beta deposits.
8 people were given placebo, 15 people were given 20 million MSCs, and 10 people were given 100 million MSCs.
Primary endpoint was treatment-emergent serious adverse events (TE-SAEs) within 30 days of infusion.
One died (low dose group) in an assisted living facility 144 days after infusion, presumably of age-related diseases.
No adverse events, serious or otherwise, were determined to be related to the infusion.
VEGF and IL-6 is significantly higher in the high-dose group than the placebo group.
Effects on cognitive decline were less clear than the biomarker studies.
More participants will better prove or disprove the effectiveness of Lomecel-B for Alzheimer’s disease.
This research was supported by two grants from the Alzheimer's Association awarded to Longeveron.
Research published in journal of the Alzheimer’s Association.
